Live on Bloomberg TV

00:00How quickly can some of these clearances be actually given. Hi good morning Christine. So obviously in the U.S. we have the FDA meeting coming up on the 10th of December. So it's possible that they move on that pretty quickly the next day or the day after. And then in Europe this is the culmination of a process that started off sometime in early October where the companies have been filing their manufacturing details et cetera paperwork. And now they've completed the file with all the data. There's no new data in the press release. So it's possible that we should get a European response by the before the end of the year as well. Is it a bigger challenge to get regulatory approval Sam or is it than actually a bigger challenge to get out there and have a distribution system where people get vaccinated in a timely fashion. Yes. The regulatory side of things. Really really good question. Folks. On the regulatory side of things is a is is a well process. And in this particular case the regulators have been involved all along. Across the Atlantic and across the globe. So there should be little room for major surprise unless there's something in the data that they don't like which would be really surprising given that the companies have built up so much hope around the vaccines. So I think distribution and of course then the usual problem of getting people through the door to take a job is going to be their biggest challenge in my view. Just to add a little bit of color to the news that's breaking that Pfizer and biotech are going to see. Conditional European clearance for their covered 19 vaccine. They also have sought conditional clearance in the regulatory submissions in other countries around the world including Australia Canada and Japan. Again trying to expedite the rollout of the vaccine trying to get it into distribution and to quote you Sam to get those jabs in the arm by the end of the year. When we talk about the rollout of this program when do we start to see the critical mass. When do we start to see these shots being distributed beyond perhaps the older care homes as well as the first healthcare responders. Yeah I think that I would expect to see some of that happening in getting close to the end of the first quarter. It'll depend on when the doses start flowing. So if you for example take the UK as an example you would have something in the region of enough doses for about twenty three and a half million people from Pfizer on Laguna. I suspect that will cover they definitely cover the health care workers and front line workers and then some of the more susceptible folks in the India age bracket above 65. So look but but to get beyond that we need to see my view and we need to go into the back end of Q1 into Q2.

No schedule data available.

Pfizer, BioNTech Seek Covid-19 Vaccine Clearance for Europe

Pfizer Inc. and BioNTech SE submitted their formal application Monday for regulatory clearance of their Covid-19 vaccine in Europe. Bloomberg Intelligence’s Sam Fazeli has the details on “Bloomberg Surveillance.” (Source: Bloomberg)

More From Bloomberg Surveillance
All episodes and clips

Bloomberg Technology
The only daily news program focused exclusively on technology, innovation and the future of business from San Francisco. Hosted by Emily Chang.
More episodes and clips